| pubmed-article:11167753 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11167753 | lifeskim:mentions | umls-concept:C1518999 | lld:lifeskim |
| pubmed-article:11167753 | lifeskim:mentions | umls-concept:C0300926 | lld:lifeskim |
| pubmed-article:11167753 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
| pubmed-article:11167753 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:11167753 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
| pubmed-article:11167753 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11167753 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11167753 | pubmed:abstractText | The type of regimen used might result in mobilization of phenotypically and functionally different CD34(+) cells. We compared the phenotype of CD34(+) cells in leukapheresis products of three homogeneous groups: I, healthy individuals treated with granulocyte colony-stimulating factor (G-CSF) alone (n = 13); II, patients mobilized with G-CSF following chemotherapy (n = 16); and III, patients mobilized with G-CSF after high-dose chemotherapeutic pretreatment (n = 24). Multiparameter flow cytometry was performed for CD34(+) subpopulation analysis and focused on adhesion molecules, differentiation markers and megakaryocytic markers relevant for stem cell homing, with special reference to the importance of L-selectin expression. Regimens I and II led to higher numbers of mobilized CD34(+) cells (mean 468 x 10(6) and 491 x 10(6) CD34(+) cells per leukapheresis procedure respectively) than regimen III (mean 41 x 10(6) CD34(+) cells per leukapheresis procedure). Both the expression of L-selectin and CD54 on CD34(+) cells was significantly lower in group III, as was the percentage of megakaryocytic (CD41(+)) progenitors. A higher percentage of primitive (CD38(-) and/or HLA(-)DR(-)) CD34(+) cells was found in group III, correlating with a higher clonogenicity of the CD34(+) cells. However, when comparing the CD34(+)_ subpopulations that were also positive for L-selectin, there was no significant difference between the three regimens. A similar approach for the megakaryocytic CD34+ population resulted in an even worse quality of regimen III: 5.1% of CD34(+) being CD41(+)/L-selectin(+) compared with 9.2% and 8.9% in regimens I and II respectively. We concluded that the phenotypes of the CD34(+) cells in the G-CSF (group I) and G-CSF-chemotherapy (group II) regimens are similar, whereas the phenotype of the CD34(+) cells mobilized in the high-dose regimen (group III) displayed features that might negatively influence homing of the cells. Future studies will be directed towards regimens that will lead to the mobilization of a higher amount of CD34(+) cells with a phenotypically favourable phenotype. | lld:pubmed |
| pubmed-article:11167753 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11167753 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11167753 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11167753 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:11167753 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:HuijgensP CPC | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:de BoerFF | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:PinedoH MHM | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:KesslerFF | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:SchuurhuisG... | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:van der... | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:DrägerA MAM | lld:pubmed |
| pubmed-article:11167753 | pubmed:author | pubmed-author:Van... | lld:pubmed |
| pubmed-article:11167753 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11167753 | pubmed:volume | 111 | lld:pubmed |
| pubmed-article:11167753 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11167753 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11167753 | pubmed:pagination | 1138-44 | lld:pubmed |
| pubmed-article:11167753 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:meshHeading | pubmed-meshheading:11167753... | lld:pubmed |
| pubmed-article:11167753 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11167753 | pubmed:articleTitle | The phenotypic profile of CD34-positive peripheral blood stem cells in different mobilization regimens. | lld:pubmed |
| pubmed-article:11167753 | pubmed:affiliation | Department of Medical Oncology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands. | lld:pubmed |
| pubmed-article:11167753 | pubmed:publicationType | Journal Article | lld:pubmed |
